EP
TVTX icon

Essential Partners’s Travere Therapeutics TVTX Stock Holding History

Essential Partners’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.8K Sell
295
-98
-25% -$4.34K 0.01% 974
2026
Q1 		$11.7K Hold
393
– – ﹤0.01% 1175
2025
Q4 		$15K Buy
393
+112
+40% +$3.64K ﹤0.01% 1011
2025
Q3 		$6.72K Sell
281
-396
-58% -$7.45K ﹤0.01% 1306
2025
Q2 		$10K Buy
+677
New +$11.2K ﹤0.01% 847

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Essential Partners's TVTX Position: Q2 2026 in Review

Essential Partners reduced its Travere Therapeutics (TVTX) stake by 25% in Q2 2026, selling an estimated $4.34K and leaving 295 shares worth $16.8K. The position accounts for 0.01% of the portfolio, ranked #974.

Essential Partners first reported a position in TVTX in Q2 2025 and has held it in 5 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Essential Partners held 295 shares of Travere Therapeutics worth $16.8K as of Q2 2026.
  • Essential Partners sold 98 Travere Therapeutics shares in Q2 2026, an estimated $4.34K.
  • Travere Therapeutics made up 0.01% of Essential Partners's portfolio in Q2 2026, its #974 holding.
  • Essential Partners first reported a position in Travere Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.